Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla(KPC-3) Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce Klebsiella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidime-avibactam resistance to develop during treatment of CRE infections and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Shields, Ryan K., Chen, Liang, Cheng, Shaoji, Chavda, Kalyan D., Press, Ellen G., Snyder, Avin, Pandey, Ruchi, Doi, Yohei, Kreiswirth, Barry N., Nguyen, M. Hong, Clancy, Cornelius J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2017
Materias:
Mechanisms of Resistance
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5328542/
https://ncbi.nlm.nih.gov/pubmed/28031201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02097-16
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares